scispace - formally typeset
A

Alison L. Harte

Researcher at University of Warwick

Publications -  53
Citations -  5119

Alison L. Harte is an academic researcher from University of Warwick. The author has contributed to research in topics: Adipose tissue & Insulin. The author has an hindex of 31, co-authored 53 publications receiving 4707 citations. Previous affiliations of Alison L. Harte include University Hospitals Coventry and Warwickshire NHS Trust & University Hospital Coventry.

Papers
More filters
Journal ArticleDOI

Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes

TL;DR: T2DM is associated with increased endotoxemia, with AT able to initiate an innate immune response, and increased adiposity may increase proinflammatory cytokines and therefore contribute to the pathogenic risk of T2DM.
Journal ArticleDOI

Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease

TL;DR: Epicardial and omental fat exhibit a broadly comparable pathogenic mRNA profile, this may arise in part from macrophage infiltration into the epicardial fat.
Journal ArticleDOI

Resistin, central obesity, and type 2 diabetes.

TL;DR: Increased resistin expression in abdominal fat could explain the increased risk of type 2 diabetes associated with central obesity.
Journal ArticleDOI

Elevated endotoxin levels in non-alcoholic fatty liver disease

TL;DR: Results suggest elevated endotoxin may serve as an early indicator of potential liver damage, perhaps negating the need for invasive liver biopsy, and interventions aimed at reducing endotoxin levels in NAFLD patients may prove beneficial in reducing inflammatory burden.
Journal ArticleDOI

Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.

TL;DR: Elevated serum resistin in human diabetes reflects the subclinical inflammation prevalent in type 2 diabetes and suppression of resistin expression may contribute to the insulin-sensitizing and glucose-lowering actions of the thiazolidinediones.